Exenatide Synthetic Injectable Suspension, Extended Release Shortage
Last Updated: October 28, 2024
Status: Discontinued
To Be Discontinued:
Bydureon BCise, Injectable Suspension, Extended Release, 2 mg/.85 mL (AstraZeneca AB)
NDC Code: 0310-6540-04Status: To Be Discontinued
Date of update: October 28, 2024
Update type: New
Therapeutic category: Endocrinology/Metabolism
Date discontinued: October 28, 2024
Initial posting date: October 28, 2024
Contact info: 800-236-9933
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.